SCHEMBL3528663

SCHEMBL3528663

Nc1ccc(-c2csc3c(-c4ccoc4)cnc(N)c23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 10/20 0.59
KDR P35968 8/20 0.59
AURKA O14965 5/20 0.59
PLK4 O00444 4/20 0.59
MAP4K4 O95819 4/20 0.59
ABL1 P00519 4/20 0.59
NTRK1 P04629 4/20 0.59
FYN P06241 4/20 0.59
CSF1R P07333 4/20 0.59
LYN P07948 4/20 0.59
FGFR1 P11362 4/20 0.59
SRC P12931 4/20 0.59
FLT1 P17948 4/20 0.59
RPS6KB1 P23443 4/20 0.59
FLT4 P35916 4/20 0.59
BLK P51451 4/20 0.59
ITK Q08881 4/20 0.59
MAP4K2 Q12851 4/20 0.59
NTRK2 Q16620 4/20 0.59
MINK1 Q8N4C8 4/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528912 0.89 BTK (0.61) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3534031 0.85 BTK (0.76) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3565790 0.83 BTK (0.67) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3529981 0.83 BTK (0.70) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3531844 0.82 KDR (0.57) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3529381 0.82 BTK (0.58) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3530274 0.82 BTK (0.49) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3532547 0.80 KDR (0.58) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3528737 0.79 BTK (0.52) BTKKDRAURKAPLK4MAP4K4
SCHEMBL3578809 0.79 BTK (0.55) BTKKDRAURKAMAP4K4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103087078-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB 2013-05-08 CN disclosed
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
CN-1856498-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB (US) 2006-11-01 CN disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK BTK 103/4885KDR 494/4885AURKA 207/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK BTK 103/4885KDR 494/4885AURKA 207/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK BTK 103/4885KDR 494/4885AURKA 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.